STOCK TITAN

OneMedNet Reports Third Quarter 2026 Financial Results and Reiterates Fourth Quarter 2026 Outlook

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

OneMedNet (ONMD) reported third-quarter 2026 revenue of $1.02 million and reiterated its revenue outlook for the fourth quarter of 2026. Revenue increased 250% from the second quarter of 2026 and 478% from the third quarter of 2025. Revenue for the first nine months of 2026 was $1.41 million. The quarterly result was consistent with the preliminary revenue of approximately $1 million announced on November 6, 2026.

The company reiterated fourth-quarter revenue guidance of approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data by quarter-end. OneMedNet said its sales funnel grew during 2026 and that it began delivering against that funnel at scale in the third quarter. The company expects revenue to occur at a faster pace in the fourth quarter, reflecting order timing and scaled delivery.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter 2026 revenue reached $1.02 million, up 250% sequentially and 478% year over year.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter 2026 revenue guidance reiterated at approximately $12 million to $14 million.
  • Moderate pointScaled delivery against the sales funnel began in the third quarter of 2026.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter guidance depends on anticipated customer acceptance of delivered data by quarter-end.

News Explained

The third-quarter figures show that, at September 30, 2026, OneMedNet had $137,000 in cash and equivalents against a third-quarter operating cash outflow of $1.422 million; at that historical rate, the balance equals 8.9 days of operating cash use.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $137,000 / ($1,422,000 / 92) = 8.9 days

Key Figures

Nine-month revenue: $1.41 million Third-quarter revenue: $1.02 million Sequential revenue growth: 250% +2 more
Nine-month revenue
$1.41 million
First nine months of 2026
Third-quarter revenue
$1.02 million
Quarter ended September 30, 2026
Sequential revenue growth
250%
Third quarter 2026 vs. second quarter 2026
Year-over-year revenue growth
478%
Third quarter 2026 vs. third quarter 2025
Fourth-quarter revenue guidance
approximately $12 million to $14 million
Fourth quarter of 2026; pending anticipated customer acceptance of delivered data

Historical Context

1 past event · Latest: Nov 06
1 event
  1. Nov 06

    Q3 revenue outlook

    24h Move
    +23.3%

    Preliminary third-quarter revenue and fourth-quarter guidance were followed by reported results and reiterated guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

real-world data, form 10-q, de-identification
3 terms
real-world data medical
"provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD)"
Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.
form 10-q regulatory
"as reported in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission"
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.
de-identification technical
"a de-identification pipeline and delivery infrastructure built to scale with demand"
The process of removing or altering personal identifiers from a dataset so individuals cannot reasonably be identified. In regulated settings (for example under HIPAA) de-identification can be achieved by removing specified direct identifiers or by a qualified expert’s determination that the risk of re-identification is very small; common techniques include deleting names and ID numbers, masking or generalizing dates and locations, and applying statistical or cryptographic transformations to quasi‑identifiers. De-identified data is treated differently than identifiable personal data under many laws and policies, but it is not risk-free: re-identification can occur if remaining details are combined with other information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MINNEAPOLIS, Nov. 17, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), announced financial results for the third quarter ended September 30, 2026, as reported in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and reiterates its revenue guidance for the fourth quarter of 2026.

The Company reported revenue of $1.41 million for the first nine months of 2026 which included $1.02 million for the quarter ended September 30, 2026, representing a 250% increase from the prior quarter ended June 30, 2026, and a 478% increase from the prior-year quarter ended September 30, 2025. These results are consistent with the prior release announced by the Company on November 6, 2026.

The Company reiterates its revenue guidance of approximately $12 million to $14 million for the fourth quarter of 2026, pending the anticipated acceptance of delivered data by customers. OneMedNet’s sales funnel grew substantially over the course of 2026, and the Company began delivering on that funnel at scale during the third quarter. Consistent with order timing combined with scaled delivery, 2026 revenue is weighted to occur at a faster pace in the fourth quarter of 2026.

“Our third quarter results confirm the delivery momentum we previewed earlier this month,” said Aaron Green, President & CEO of OneMedNet. “The hardest work in this business — curating, de-identifying, and delivering regulatory-grade multimodal data at scale — is substantially complete. With our First-Party data coming directly from our healthcare provider partners and a de-identification pipeline and delivery infrastructure built to scale with demand, we are now converting our contracted demand into delivered data, and we remain focused on finishing the year with the fourth quarter we have guided to.”

Third Quarter 2026 Results and Fourth Quarter Outlook Highlights

  • Third quarter 2026 revenue of $1.02 million, consistent with the preliminary revenue of approximately $1 million reported on November 6, 2026.
  • Sequential growth of 250% over the second quarter of 2026 and year-over-year growth of 478% over the third quarter of 2025.
  • Reiterates fourth quarter 2026 revenue guidance of approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data by quarter-end.

The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including complete financial statements and management’s discussion and analysis, is available on the SEC’s website at www.sec.gov and in the Investors section of the Company’s website at www.onemednet.com.

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our revenue outlook for the fourth quarter of 2026, the timing of revenue recognition, the anticipation of data delivery and customer acceptance, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include but are not limited to our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing

Email: Michael.Wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did OneMedNet report for the third quarter of 2026?

OneMedNet reported $1.02 million in third-quarter 2026 revenue, an increase of 250% from the second quarter of 2026 and 478% from the third quarter of 2025.

What is OneMedNet's fourth-quarter 2026 revenue guidance?

OneMedNet reiterated fourth-quarter 2026 revenue guidance of approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data by quarter-end.

Keep reading